肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021

2021-12-25 中国临床肿瘤学会指南工作委员会 肿瘤预防与治疗

甲状腺甲状腺癌分化型甲状腺癌

基于循证医学证据、兼顾诊疗产品的可及性、吸收精准医学新进展,制定中国常见癌症的诊断和治疗指南,是中国临床肿瘤学会(CSCO)的基本任务之一。

中文标题：

中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021

发布机构：

中国临床肿瘤学会指南工作委员会

发布日期：

2021-12-25

简要介绍：

基于循证医学证据、兼顾诊疗产品的可及性、吸收精准医学新进展,制定中国常见癌症的诊断和治疗指南,是中国临床肿瘤学会(CSCO)的基本任务之一。近年来,临床诊疗指南的制定出现新的趋向,即基于诊疗资源的可及性,这尤其适合发展中或地区差异性显著的国家和地区。中国是幅员辽阔,地区经济和学术发展不平衡的发展中国家,CSCO指南需要兼顾地区发展差异、药物和诊疗手段的可及性以及肿瘤治疗的社会价值三个方面。因此,CSCO指南的制定,要求每一个临床问题的诊疗意见,需根据循证医学证据和专家共识度形成证据类别,同时结合产品的可及性和效价比形成推荐等级。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021.pdf)] GetToolGuiderByIdResponse(projectId=1, id=89d491c0023a54a6, title=中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021, enTitle=, guiderFrom=肿瘤预防与治疗, authorId=0, author=, summary=基于循证医学证据、兼顾诊疗产品的可及性、吸收精准医学新进展,制定中国常见癌症的诊断和治疗指南,是中国临床肿瘤学会(CSCO)的基本任务之一。, cover=https://img.medsci.cn/202223/1643855954876_5579292.png, journalId=0, articlesId=null, associationId=1983, associationName=中国临床肿瘤学会指南工作委员会, associationIntro=中国临床肿瘤学会指南工作委员会, copyright=0, guiderPublishedTime=Sat Dec 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">基于循证医学证据、兼顾诊疗产品的可及性、吸收精准医学新进展,制定中国常见癌症的诊断和治疗指南,是中国临床肿瘤学会(CSCO)的基本任务之一。近年来,临床诊疗指南的制定出现新的趋向,即基于诊疗资源的可及性,这尤其适合发展中或地区差异性显著的国家和地区。中国是幅员辽阔,地区经济和学术发展不平衡的发展中国家,CSCO指南需要兼顾地区发展差异、药物和诊疗手段的可及性以及肿瘤治疗的社会价值三个方面。因此,CSCO指南的制定,要求每一个临床问题的诊疗意见,需根据循证医学证据和专家共识度形成证据类别,同时结合产品的可及性和效价比形成推荐等级。&nbsp;</span></p>, tagList=[TagDto(tagId=736, tagName=甲状腺), TagDto(tagId=865, tagName=甲状腺癌), TagDto(tagId=7891, tagName=分化型甲状腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7053, appHits=353, showAppHits=0, pcHits=1243, showPcHits=6698, likes=2, shares=73, comments=12, approvalStatus=1, publishedTime=Tue Feb 08 15:34:00 CST 2022, publishedTimeString=2021-12-25, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Feb 03 10:41:10 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 19:52:41 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021.pdf)])
中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2088984, encodeId=4ec72088984c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:52:52 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224648, encodeId=17951224648af, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL2qEM6CTdm3icd2KY7AuDAIEGH9kvcbHQVhibnLuFbf2MhzKqEyib3AribelLfBaS87mibR7YtJdc4JrA/132, createdBy=9dbc5307831, createdName=docyyx, createdTime=Sun Jun 05 23:33:48 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209403, encodeId=ce10120940370, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdeb5452533, createdName=ms5000000777054870, createdTime=Thu Apr 07 23:14:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200936, encodeId=514b120093647, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d5519902, createdName=ms2000001051871447, createdTime=Wed Mar 09 16:51:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195412, encodeId=762411954124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d05a5574909, createdName=ms7000000909951304, createdTime=Sun Feb 20 18:43:15 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-09-19 1471d48dm72暂无昵称

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2088984, encodeId=4ec72088984c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:52:52 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224648, encodeId=17951224648af, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL2qEM6CTdm3icd2KY7AuDAIEGH9kvcbHQVhibnLuFbf2MhzKqEyib3AribelLfBaS87mibR7YtJdc4JrA/132, createdBy=9dbc5307831, createdName=docyyx, createdTime=Sun Jun 05 23:33:48 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209403, encodeId=ce10120940370, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdeb5452533, createdName=ms5000000777054870, createdTime=Thu Apr 07 23:14:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200936, encodeId=514b120093647, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d5519902, createdName=ms2000001051871447, createdTime=Wed Mar 09 16:51:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195412, encodeId=762411954124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d05a5574909, createdName=ms7000000909951304, createdTime=Sun Feb 20 18:43:15 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-06-05 docyyx

    实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2088984, encodeId=4ec72088984c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:52:52 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224648, encodeId=17951224648af, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL2qEM6CTdm3icd2KY7AuDAIEGH9kvcbHQVhibnLuFbf2MhzKqEyib3AribelLfBaS87mibR7YtJdc4JrA/132, createdBy=9dbc5307831, createdName=docyyx, createdTime=Sun Jun 05 23:33:48 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209403, encodeId=ce10120940370, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdeb5452533, createdName=ms5000000777054870, createdTime=Thu Apr 07 23:14:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200936, encodeId=514b120093647, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d5519902, createdName=ms2000001051871447, createdTime=Wed Mar 09 16:51:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195412, encodeId=762411954124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d05a5574909, createdName=ms7000000909951304, createdTime=Sun Feb 20 18:43:15 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-04-07 ms5000000777054870

    值得学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2088984, encodeId=4ec72088984c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:52:52 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224648, encodeId=17951224648af, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL2qEM6CTdm3icd2KY7AuDAIEGH9kvcbHQVhibnLuFbf2MhzKqEyib3AribelLfBaS87mibR7YtJdc4JrA/132, createdBy=9dbc5307831, createdName=docyyx, createdTime=Sun Jun 05 23:33:48 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209403, encodeId=ce10120940370, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdeb5452533, createdName=ms5000000777054870, createdTime=Thu Apr 07 23:14:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200936, encodeId=514b120093647, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d5519902, createdName=ms2000001051871447, createdTime=Wed Mar 09 16:51:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195412, encodeId=762411954124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d05a5574909, createdName=ms7000000909951304, createdTime=Sun Feb 20 18:43:15 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-03-09 ms2000001051871447

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2088984, encodeId=4ec72088984c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:52:52 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1224648, encodeId=17951224648af, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTL2qEM6CTdm3icd2KY7AuDAIEGH9kvcbHQVhibnLuFbf2MhzKqEyib3AribelLfBaS87mibR7YtJdc4JrA/132, createdBy=9dbc5307831, createdName=docyyx, createdTime=Sun Jun 05 23:33:48 CST 2022, time=2022-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1209403, encodeId=ce10120940370, content=值得学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdeb5452533, createdName=ms5000000777054870, createdTime=Thu Apr 07 23:14:02 CST 2022, time=2022-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200936, encodeId=514b120093647, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d5519902, createdName=ms2000001051871447, createdTime=Wed Mar 09 16:51:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195412, encodeId=762411954124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d05a5574909, createdName=ms7000000909951304, createdTime=Sun Feb 20 18:43:15 CST 2022, time=2022-02-20, status=1, ipAttribution=)]
    2022-02-20 ms7000000909951304

    学习了

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2022 ETA指南：儿童 Graves'病的管理

欧洲甲状腺协会(ETA,European Thyroid Association) · 2022-01-01

2021 INMSG共识声明：甲状腺和甲状旁腺手术中神经监测的知情同意

国际神经监测学组(INMSG,International Neural Monitoring Study Group) · 2021-12-07

2021 ESA立场声明：成人原发性甲状旁腺功能亢进的评估和药物治疗

澳大利亚内分泌学会(ESA,Endocrine Society of Australia) · 2021-12-21

2021 ESA立场声明：成人原发性甲状旁腺功能亢进的手术治疗和术后随访

澳大利亚内分泌学会(ESA,Endocrine Society of Australia) · 2021-12-19

桥本氏甲状腺炎中西医结合质量控制指标体系北京专家共识（2021版）

北京中西医结合学会甲状腺病专业委员会 · 2021-12-10

《2020～2021年欧洲内分泌参考网共识指南：先天性甲状腺功能减低症》解读

暂未更新 · 2021-11-15